We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Successful treatment of a child with MEK inhibitor‐induced acneiform eruption with low‐dose isotretinoin.
- Authors
Gupta, Rohit; Craddock, Megan F.
- Abstract
Selumetinib is a mitogen‐activated protein kinase/extracellular signal‐regulated kinase inhibitor (MEKi) approved to treat inoperable plexiform neurofibromas and used off‐label for low‐grade gliomas. Acneiform eruptions are a known complication of MEKi use, and in some cases, may lead to paused, dose‐reduced, or discontinued therapy. Isotretinoin has been reported as an effective treatment for acneiform eruptions secondary to targeted therapies, primarily in the adult population. Here we describe a pediatric patient with a severe acneiform eruption secondary to selumetinib who was successfully treated with low‐dose isotretinoin when unresponsive to conventional therapies.
- Subjects
ACNEIFORM eruptions; MITOGEN-activated protein kinases; TREATMENT effectiveness; ISOTRETINOIN; CHILD patients; OFF-label use (Drugs)
- Publication
Pediatric Dermatology, 2022, Vol 39, Issue 4, p646
- ISSN
0736-8046
- Publication type
Article
- DOI
10.1111/pde.14959